Clinical Data GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail BioSpaceCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, "is unlikely to transform patient care," the pharma said.RespiratoryRead full story pharminent July 17, 2026 (Last updated: July 20, 2026) BioSpace Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said. Respiratory Read full story Post navigation Previous: FDA grants traditional approval to Novartis’ Fabhalta for IgANNext: Novo Lands European Oral Wegovy Approval Before Lilly Can Respond Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026